
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SJ-600
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : ReiThera
Deal Size : Undisclosed
Deal Type : Partnership
ReiThera Partners with SillaJen to Develop & Produce the SJ-600 Series for Clinical Trials
Details : Through the partnership, ReiThera will leverage its expertise to conduct advanced development & production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 24, 2025
Lead Product(s) : SJ-600
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : ReiThera
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : OSR Holdings
Deal Size : Undisclosed
Deal Type : Collaboration
OSR Holdings and SillaJen Sign MOU to Develop Innovative Therapeutics in US Market
Details : The collaboration will explore various ways to create synergies between current platform technologies and new drug candidates, including BAL0891, a mitotic checkpoint inhibitor targeting solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : OSR Holdings
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Details : Pexa-Vec (pexastimogene devacirepvec) is a vaccinia virus based oncolytic immunotherapy is being evaluated in combination with cemiplimab for metastatic or unresectable renal cell carcinoma.
Product Name : Pexa-Vec
Product Type : Microorganism
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Details : BAL0891 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Basilea Pharmaceutica
Deal Size : $14.0 million
Deal Type : Agreement
Details : BAL0891 is a potential first-in-class mitotic checkpoint inhibitor that drives aberrant tumor cell division leading to tumor cell death. A first poster showed in-vitro data on the activity of BAL0891 against its targets, threonine tyrosine kinase and pol...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
December 19, 2022
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Basilea Pharmaceutica
Deal Size : $14.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Basilea Pharmaceutica
Deal Size : $334.0 million
Deal Type : Licensing Agreement
Details : The agreement for a novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, demonstrates the commitment to enhance lives of patients suffering from advanced solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Basilea Pharmaceutica
Deal Size : $334.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Pexa Vec
Product Type : Microorganism
Upfront Cash : Inapplicable
September 26, 2017
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Pexa Vec
Product Type : Microorganism
Upfront Cash : Inapplicable
September 29, 2015
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 10, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : JX-594
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Transgene
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 15, 2011
Lead Product(s) : JX-594
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Transgene
Deal Size : Inapplicable
Deal Type : Inapplicable
